<DOC>
	<DOCNO>NCT00005610</DOCNO>
	<brief_summary>RATIONALE : Colony-stimulating factor , sargramostim , may help body 's immune system kill cancer cell . Giving sargramostim different way may kill cancer cell . PURPOSE : Phase II trial study effectiveness sargramostim give breathe treatment treat patient melanoma metastatic lung .</brief_summary>
	<brief_title>Study Aerosolized Sargramostim Treating Patients With Melanoma Metastatic Lung</brief_title>
	<detailed_description>OBJECTIVES : I . Determine therapeutic effect aerosolize sargramostim ( GM-CSF ) term progression free survival 2 month median survival rate patient metastatic melanoma lung . II . Determine immunomodulatory effect treatment regimen patient population . III . Assess quality life term physical personal concern patient treat regimen . OUTLINE : Patients receive aerosolize sargramostim ( GM-CSF ) 10-15 minute twice daily 7 day . Treatment repeat every 2 week 4 course absence disease progression unacceptable toxicity . Quality life assess baseline prior course 5 . Patients follow every 2 month least 1.5 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm melanoma radiographic evidence prior active involvement lung pleura Measurable disease At least one lesion least one dimension diameter least 10 mm CT scan MRI No nonmeasurable disease include follow : Bone lesion Leptomeningeal disease Ascites Pleural pericardial effusion Inflammatory breast disease Lymphangitis cutis pulmonis Unconfirmed abdominal mass follow image Cystic lesion PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,000/mm3 Platelet count least 75,000/mm3 Hemoglobin least 8.0 g/dL Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST great 3 time ULN Renal : Creatinine great 2.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease Other : No uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 week since prior biologic immunotherapy No concurrent biologic immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) No concurrent chemotherapy Endocrine therapy : At least 2 week since prior corticosteroid No concurrent systemic glucocorticosteroids Radiotherapy : At least 2 week since prior radiotherapy No concurrent radiotherapy Surgery : Not specify Other : No concurrent immunosuppressant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>lung metastasis</keyword>
</DOC>